| Literature DB >> 28182108 |
Ewelina Gowin1, Alicja Bartkowska-Śniatkowska2, Katarzyna Jończyk-Potoczna3, Joanna Wysocka-Leszczyńska4, Waldemar Bobkowski5, Piotr Fichna6, Paulina Sobkowiak7, Katarzyna Mazur-Melewska8, Anna Bręborowicz9, Jacek Wysocki10, Danuta Januszkiewicz-Lewandowska11.
Abstract
The aim of the study was assessment of the usefulness of multiplex real-time PCR tests in the diagnostic and therapeutic process in children hospitalized due to pneumonia and burdened with comorbidities. Methods. The study group included 97 children hospitalized due to pneumonia at the Karol Jonscher Teaching Hospital in Poznań, in whom multiplex real-time PCR tests (FTD respiratory pathogens 33; fast-track diagnostics) were used. Results. Positive test results of the test were achieved in 74 patients (76.3%). The average age in the group was 56 months. Viruses were detected in 61 samples (82% of all positive results); bacterial factors were found in 29 samples (39% of all positive results). The presence of comorbidities was established in 90 children (92.78%). On the basis of the obtained results, 5 groups of patients were established: viral etiology of infection, 34 patients; bacterial etiology, 7 patients; mixed etiology, 23 patients; pneumocystis, 9 patients; and no etiology diagnosed, 24 patients. Conclusions. Our analysis demonstrated that the participation of viruses in causing severe lung infections is significant in children with comorbidities. Multiplex real-time PCR tests proved to be more useful in establishing the etiology of pneumonia in hospitalized children than the traditional microbiological examinations.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28182108 PMCID: PMC5274672 DOI: 10.1155/2017/8037963
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Characteristics of study subjects.
| Number of patients | 97 |
| Mean age (months) | 56.3 |
| Male/female ratio | 52/45 |
| ICU admission | 53 (54%) |
| Airways obturation | 44 (44%) |
| Coexisting diseases | 90 (92.78%) |
| Heart diseases | 21 (20%) |
| CHD | 17 |
| HF | 2 |
| HA | 1 |
| Neurologic diseases | 13 (13%) |
| Cerebral palsy | 7 |
| Epilepsy | 4 |
| Myopathy | 2 |
| Neoplastic diseases | 9 (9%) |
| ALL | 6 |
| Solid tumor | 3 |
| Pulmonary diseases | 12 (12%) |
| Asthma | 8 |
| CF | 4 |
| Immunosuppression | 11 (11%) |
| Malnutrition | 41 (42%) |
| FTD 33 and microbiology results | |
| FTD 33+/microbiology− | 63 (65%) |
| FTD 33+/microbiology+ | 11 (11%) |
| FTD 33−/microbiology+ | 6 (6%) |
| FTD 33−/microbiology− | 17 (18%) |
ALL: acute lymphoblastic leukemia, CF: cystic fibrosis, CHD: congenital heart defect, FTD 33−: FTD respiratory pathogens 33 test negative results, FTD 33+: FTD respiratory pathogens 33 test positive results, HA: hypertension, HF heart failure, ICU: Intensive Care Unit, microbiology: microbiological cultures negative results, and microbiology+: microbiological cultures positive results.
Prevalence of pathogens and rates of codetection.
| Single pathogen | Bacterial coinfection | Viral coinfection | Coinfection with | Mixed coinfection viral and bacterial | Total number | |
|---|---|---|---|---|---|---|
|
| 0 | 1 | 11 | 0 | 2 | 14 |
|
| 0 | 2 | 3 | 0 | 3 | 8 |
|
| 3 | 3 | 2 | 0 | 3 | 11 |
|
| 0 | 0 | 1 | 0 | 1 | 2 |
|
| 0 | 0 | 2 | 0 | 1 | 3 |
|
| 1 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 1 | 0 | 1 | 3 |
| RSV | 11 | 4 | 6 | 1 | 1 | 23 |
| RH | 5 | 4 | 2 | 1 | 7 | 19 |
| AdV | 3 | 1 | 2 | 0 | 5 | 11 |
| hMPV | 3 | 0 | 2 | 0 | 2 | 7 |
| CMV | 1 | 1 | 2 | 2 | 4 | 10 |
| INF | 0 | 1 | 0 | 0 | 0 | 1 |
| ENTERO | 1 | 1 | 0 | 0 | 0 | 2 |
| PINF | 1 | 0 | 2 | 0 | 0 | 3 |
| CORO | 1 | 2 | 0 | 0 | 2 | 5 |
| BOC | 1 | 1 | 0 | 1 | 0 | 3 |
| PNP | 4 | 0 | 4 | 0 | 1 | 9 |
AdV: adenovirus; BOC: bocavirus, CMV: cytomegalovirus, CORO: coronavirus, Entero: enteroviruses, hMPV: human metapneumovirus, INF: influenza virus, PINF: human parainfluenza virus; PNP: Pneumocystis jiroveci, RH: rhinovirus; and RSV: respiratory syncytial virus.
Figure 1Results of nasopharyngeal samples analyzed by multiplex real-time PCR in relation to age groups. AdV: adenovirus; Boc: bocavirus; CMV: cytomegalovirus; Coro: coronavirus; Entero: enterovirus, hMPV: human metapneumovirus; INF: influenza virus; PINF: human parainfluenza virus; RH: rhinovirus; RSV: respiratory syncytial virus.
Results of diagnostic test in patients with at least one positive microbiology culture.
| Blood culture | Nasal swab | Respiratory tract aspirate | PCR |
|---|---|---|---|
| Positive blood culture | |||
|
| Sa | Pseud | 0 |
|
| Sa | X | 0 |
|
| Pseud | Pseud | 0 |
| Positive respiratory tract aspirate | |||
| 0 | X | Sa | RH/AdV/Sa |
| X | X | Sp | RH/Sp |
| 0 | X | Hinf, Klebs | RH/Hinf |
| 0 | X | Hinf | RSV/Hinf |
| 0 | X | Hinf | RH/AdV/Hinf |
| 0 | F |
| RSV/CMV/Hinf |
| X | X | Hinf | PINF/Sa |
| 0 | 0 | Sa | RSV |
| X | F | Klebs | RSV |
| 0 | F | Sp | RSV |
| 0 | F | Pseud | hMPV |
| X | X | Klebs | AdV/PINF |
| Hinf | 0 | ||
| 0 | F | Sa | Sa |
| Positive nasal swab | |||
| 0 | Sa | 0 | 0 |
| X | Sa | F | RSV |
| X | Sa | X | RH |
| X | Pseud | X | Sa |
| 0 | Sa | 0 | Sa |
| X | Sa | F | CORO/Sa |
| 0 | Sa | F | Sa/INF |
| Positive nasal swab and respiratory tract aspirate | |||
| 0 | Sa | ESBL | 0 |
| 0 | Sa | Sa | RH/PNP |
| 0 | Sa | Hinf | RSV/hMPV |
| 0 | Sp | Pseud, Sp | CMV |
| 0 | Pseud | Serr, Sa | hMPV |
| X | Sa | Sa | Sa/Sp |
| 0 | Sp | Sp | BOC/Sp |
AdV: adenovirus; BOC: bocavirus; CMV: cytomegalovirus; CORO: coronavirus; E. coli: Escherichia coli; F: physiologic flora; Hinf: Haemophilus influenzae; hMPV: human metapneumovirus; Klebs: Klebsiella pneumoniae; PINF: human parainfluenza virus; PNP: Pneumocystis jiroveci; Pseud: Pseudomonas aeruginosa; RH: rhinovirus; RSV: respiratory syncytial virus; Sa: Staphylococcus aureus; Sp: Streptococcus pneumoniae; X: test not done; and 0: negative results.
Targeted therapy implemented based on FTD33 positive results.
| FTD33 | Influenza |
|
|
|
|---|---|---|---|---|
| Number of patients | 1 | 1 | 2 | 9 |
| Targeted treatment | Oseltamivir | Macrolides | Trimethoprim/ | |